カテゴリ： Transparency Market Research, 世界, 医療/バイオ

バソプレシン拮抗薬の世界市場2023～2031：用途別

■ 英語タイトル：Vasopressin Antagonists Market (Application: Central Diabetes Insipidus, Nephrogenic Diabetes Insipidus, and Other Applications) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23MA083）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23MA083
■ 発行日：2023年3月27日
■ 調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ
■ 産業分野：医薬品
■ ページ数：183
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥869,250見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,319,250見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,769,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[バソプレシン拮抗薬の世界市場2023～2031：用途別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の当調査レポートでは、世界のバソプレシン拮抗薬市場規模が、2023年の17億ドルから2031年に27億ドルとなり、予測期間中に年平均成長率4.9%で拡大すると展望しています。本書は、バソプレシン拮抗薬の世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤別（バプリゾール、トルバプタン）分析、用途別（中枢性尿崩症、腎性尿崩症、その他）分析、流通チャネル別（小売薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Otsuka、Cumberland Pharmaceuticals、Mayo Clinic、Hopital du Sacre-Coeur de Montrealなどの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のバソプレシン拮抗薬市場規模：薬剤別
- バプリゾールの市場規模
- トルバプタンの市場規模
・世界のバソプレシン拮抗薬市場規模：用途別
- 中枢性尿崩症における市場規模
- 腎性尿崩症における市場規模
- その他用途における市場規模
・世界のバソプレシン拮抗薬市場規模：流通チャネル別
- 小売薬局チャネルの市場規模
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界のバソプレシン拮抗薬市場規模：地域別
- 北米のバソプレシン拮抗薬市場規模
- ヨーロッパのバソプレシン拮抗薬市場規模
- アジア太平洋のバソプレシン拮抗薬市場規模
- 中南米のバソプレシン拮抗薬市場規模
- 中東・アフリカのバソプレシン拮抗薬市場規模
・競争状況

Vasopressin Antagonists Market – Scope of Report
TMR’s report on the global vasopressin antagonists market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vasopressin antagonists market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vasopressin antagonists market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vasopressin antagonists market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vasopressin antagonists market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vasopressin antagonists market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vasopressin antagonists market.

The report delves into the competitive landscape of the global vasopressin antagonists market. Key players operating in the global vasopressin antagonists market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vasopressin antagonists market profiled in this report.

Key Questions Answered in Global Vasopressin Antagonists Market Report
• What is the sales/revenue generated by vasopressin antagonists across all regions during the forecast period?
• What are the opportunities in the global vasopressin antagonists market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Vasopressin Antagonists Market – Research Objectives and Research Approach
The comprehensive report on the global vasopressin antagonists market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vasopressin antagonists market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vasopressin antagonists market.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vasopressin Antagonists Market
4. Market Overview
    4.1. Introduction
        4.1.1. Drug Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Incidence and Prevalence
    5.3. Regulatory Approval
    5.4. COVID-19 Impact Analysis
6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Type, 2017–2031
        6.3.1. Vaprisol
        6.3.2. Tolvaptan
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Central Diabetes Insipidus
        7.3.2. Nephrogenic Diabetes Insipidus
        7.3.3. Other Applications
    7.4. Market Attractiveness Analysis, by Application
8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Retail Pharmacies
        8.3.2. Hospital Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Vasopressin Antagonists Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Type, 2017–2031
        10.2.1. Vaprisol
        10.2.2. Tolvaptan
    10.3. Market Value Forecast, by Application, 2017–2031
        10.3.1. Central Diabetes Insipidus
        10.3.2. Nephrogenic Diabetes Insipidus
        10.3.3. Other Applications
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Retail Pharmacies
        10.4.2. Hospital Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Type
        10.6.2. By Application
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Vasopressin Antagonists Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Type, 2017–2031
        11.2.1. Vaprisol
        11.2.2. Tolvaptan
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Central Diabetes Insipidus
        11.3.2. Nephrogenic Diabetes Insipidus
        11.3.3. Other Applications
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Retail Pharmacies
        11.4.2. Hospital Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Type
        11.6.2. By Application
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Type, 2017–2031
        12.2.1. Vaprisol
        12.2.2. Tolvaptan
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Central Diabetes Insipidus
        12.3.2. Nephrogenic Diabetes Insipidus
        12.3.3. Other Applications
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Retail Pharmacies
        12.4.2. Hospital Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Type
        12.6.2. By Application
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Vasopressin Antagonists Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Type, 2017–2031
        13.2.1. Vaprisol
        13.2.2. Tolvaptan
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Central Diabetes Insipidus
        13.3.2. Nephrogenic Diabetes Insipidus
        13.3.3. Other Applications
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Retail Pharmacies
        13.4.2. Hospital Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Type
        13.6.2. By Application
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Type, 2017–2031
        14.2.1. Vaprisol
        14.2.2. Tolvaptan
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Central Diabetes Insipidus
        14.3.2. Nephrogenic Diabetes Insipidus
        14.3.3. Other Applications
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Retail Pharmacies
        14.4.2. Hospital Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Type
        14.6.2. By Application
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company, 2022
    15.3. Company Profiles
        15.3.1. Otsuka
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Test Drug Type Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Cumberland Pharmaceuticals
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Test Drug Type Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Mayo Clinic
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Test Drug Type Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Hopital du Sacre-Coeur de Montreal
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Test Drug Type Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview

List of Tables

Table 1: Global overview of Vasopressin Antagonists

Table 2: Regional overview of Vasopressin Antagonists

Table 3: North America Overview of Vasopressin Antagonists

Table 4: APAC overview of Vasopressin Antagonists

Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ペットケア糖尿病薬の世界市場2023～2031：製品タイプ別、動物種類別
  • 糖尿病装置の世界市場2022～2031：製品種類別
  • 増殖糖尿病網膜症の世界市場2023～2031：薬剤クラス別、投与形態別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23MA083 )"バソプレシン拮抗薬の世界市場2023～2031：用途別" (英文：Vasopressin Antagonists Market (Application: Central Diabetes Insipidus, Nephrogenic Diabetes Insipidus, and Other Applications) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。